LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
Digestive enzyme supplements for GLP-1 users are increasingly marketed to individuals experiencing gastrointestinal side effects from medications such as semaglutide or liraglutide. Whilst these over-the-counter products contain enzymes that break down food components, their role in managing GLP-1-related digestive symptoms is not supported by clinical evidence. GLP-1 receptor agonists slow gastric emptying rather than impairing enzyme production, meaning digestive discomfort typically stems from mechanical factors rather than enzymatic insufficiency. Understanding the difference between medication side effects and genuine enzyme deficiency is essential before considering supplementation, particularly as these products are not regulated as medicines in the UK.
Quick Answer: Digestive enzyme supplements are not clinically indicated for routine GLP-1 users, as gastrointestinal symptoms result from delayed gastric emptying rather than enzyme deficiency.
Digestive enzyme supplements are over-the-counter preparations containing enzymes that help break down food components in the gastrointestinal tract. These products typically include proteases (which digest proteins), lipases (which break down fats), and amylases (which process carbohydrates). Some formulations also contain lactase for dairy digestion or cellulase for plant fibre breakdown.
In healthy individuals, the pancreas, stomach, and small intestine naturally produce sufficient digestive enzymes. However, certain medical conditions—such as chronic pancreatitis, pancreatic insufficiency, or cystic fibrosis—can impair enzyme production, leading to malabsorption and symptoms like bloating, diarrhoea, and steatorrhoea (fatty stools). In these cases, prescription pancreatic enzyme replacement therapy (PERT) is the evidence-based treatment, available through the NHS and recommended in guidelines such as NICE NG85.
Over-the-counter digestive enzyme supplements are marketed for general digestive discomfort, but their efficacy in people without diagnosed enzyme deficiency lacks robust clinical evidence. These products are regulated as food supplements under food law by the Food Standards Agency (FSA) and local authorities, not as medicines by the MHRA. This means quality, potency, and purity can vary considerably between brands, and their enzyme units are not equivalent to prescription PERT.
For individuals taking GLP-1 receptor agonists (such as semaglutide or liraglutide), digestive symptoms are common side effects related to the medication's mechanism of action rather than enzyme deficiency. There is no established link between routine GLP-1 use and a need for enzyme supplementation, although it's worth noting that pancreatitis is a rare adverse effect that can affect enzyme production. Understanding how these medications affect digestion is essential before considering any supplementation.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
GLP-1 (glucagon-like peptide-1) receptor agonists are prescribed for type 2 diabetes management and, increasingly, for weight management as recommended in NICE guidance (NG28, TA875, TA664). These medications work by mimicking a naturally occurring hormone that regulates blood glucose and appetite. The primary mechanism of action includes stimulating insulin secretion in response to food, suppressing glucagon release, and—crucially for digestive symptoms—slowing gastric emptying.
By delaying the rate at which food leaves the stomach and enters the small intestine, GLP-1 medications prolong satiety and help control post-meal blood glucose spikes. However, this delayed gastric emptying commonly causes gastrointestinal side effects, particularly during treatment initiation or dose escalation. Patients frequently report nausea, bloating, early satiety, constipation, and occasionally vomiting, as documented in the Summary of Product Characteristics (SmPC) for medications like Ozempic, Wegovy, Saxenda and Victoza.
Importantly, GLP-1 medications do not typically impair the production or function of digestive enzymes. The pancreas generally continues to secrete enzymes normally, and the small intestine maintains its absorptive capacity. The digestive discomfort experienced by GLP-1 users stems from mechanical factors—food remaining in the stomach longer—rather than enzymatic insufficiency. However, it should be noted that pancreatitis is a rare but serious adverse effect that can affect pancreatic enzyme production.
NICE guidance on GLP-1 agonists acknowledges these gastrointestinal effects and recommends gradual dose titration to minimise symptoms. Dietary modifications—such as eating smaller, more frequent meals and avoiding high-fat foods—are the first-line approach to managing these side effects, rather than supplementation.
For oral semaglutide (Rybelsus), it's important to note that the medication should be taken on an empty stomach with a small amount of water and at least 30 minutes before food, beverages or other oral medicines, as concurrent intake may reduce absorption.
If you are considering digestive enzyme supplements whilst taking GLP-1 medication, it is essential to understand the regulatory landscape and potential risks. In the UK, most digestive enzyme products sold in health food shops or online are classified as food supplements regulated under food law by the Food Standards Agency (FSA) and local authorities. This means they are not subject to the same rigorous testing, quality control, or efficacy standards as prescription medications. The MHRA only regulates enzyme products classified as medicines or borderline products.
Consumers should purchase supplements from reputable sources and look for products that adhere to Good Manufacturing Practice (GMP) standards. However, even quality-assured products may not contain the enzyme types or concentrations needed to address genuine digestive insufficiency, and their benefit for GLP-1-related symptoms is unproven.
Potential risks of taking digestive enzyme supplements include:
Drug interactions: Some enzyme preparations may affect the absorption or metabolism of other medications. For example, the BNF notes that pancreatin can reduce the effect of acarbose (an antidiabetic medication)
Allergic reactions: Many products are derived from animal (often porcine) or fungal sources and may trigger sensitivities or have religious implications
Gastrointestinal irritation: High-dose enzyme supplements may worsen nausea or abdominal discomfort in some individuals
Masking underlying conditions: Self-treating with supplements may delay diagnosis of serious digestive disorders
Before purchasing any supplement, check the ingredient list carefully for allergens and avoid products making exaggerated health claims. The Advertising Standards Authority (ASA) and Committee of Advertising Practice (CAP) Code Section 15 prohibit misleading health claims for food supplements, but enforcement can be inconsistent, particularly for online retailers.
Consult your pharmacist before adding any supplement to your regimen, especially if you take prescription medications. If you have been prescribed GLP-1 medication through the NHS or a private provider, your prescribing clinician should be your first point of contact for managing side effects, rather than self-medicating with supplements.
Whilst mild gastrointestinal symptoms are expected when starting GLP-1 medications, certain presentations warrant medical review. You should contact your GP or prescribing clinician if you experience:
Persistent or severe nausea and vomiting that prevents adequate fluid or food intake, as this may lead to dehydration
Severe or persistent abdominal pain, particularly if localised to the upper abdomen, which could indicate pancreatitis (a rare but serious adverse effect of GLP-1 agonists)
Unexplained weight loss beyond what is expected from the medication's therapeutic effect
Changes in bowel habit lasting more than a few weeks, including persistent diarrhoea or new-onset constipation
Signs of malabsorption, such as pale, floating, foul-smelling stools (steatorrhoea), which may indicate pancreatic insufficiency
Symptoms that significantly impair quality of life or prevent you from continuing your medication
Right upper quadrant pain, fever, or yellowing of the skin/eyes, which could indicate gallbladder disease (a reported risk with GLP-1 medications)
Seek urgent medical attention via NHS 111 or 999 if you develop severe, persistent upper abdominal pain, especially with vomiting. If pancreatitis is suspected, you should stop taking your GLP-1 medication immediately and not restart without medical advice.
Your GP can assess whether symptoms are typical medication side effects or indicate an underlying condition requiring investigation. NICE guidance recommends considering dose reduction or temporary treatment interruption for troublesome gastrointestinal effects, and your clinician may suggest dietary modifications or prescribe anti-emetic medication if appropriate.
If genuine pancreatic insufficiency is suspected—particularly in patients with a history of pancreatitis, pancreatic surgery, or conditions like cystic fibrosis—your GP can arrange appropriate investigations, including faecal elastase testing (values below 200 µg/g suggest exocrine pancreatic insufficiency) and referral to gastroenterology if needed. Prescription pancreatic enzyme replacement therapy (PERT) is the evidence-based treatment for confirmed enzyme deficiency and is far more effective than over-the-counter supplements.
Do not discontinue GLP-1 medication without medical advice (except in suspected pancreatitis), as this may affect your diabetes control or weight management goals. Report any suspected side effects to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk). Your healthcare team can work with you to optimise treatment whilst managing side effects appropriately.
No, GLP-1 receptor agonists do not typically impair digestive enzyme production. Gastrointestinal symptoms result from delayed gastric emptying rather than enzymatic insufficiency, though pancreatitis is a rare adverse effect that can affect pancreatic function.
There is no clinical evidence supporting the use of over-the-counter enzyme supplements for GLP-1-related digestive symptoms. Dietary modifications and gradual dose titration are the recommended first-line approaches per NICE guidance.
Contact your GP if you experience severe or persistent abdominal pain, persistent vomiting preventing adequate intake, signs of malabsorption such as pale floating stools, or symptoms significantly impairing quality of life. Seek urgent care for severe upper abdominal pain with vomiting, as this may indicate pancreatitis.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
